Lion's Mane for MS Fatigue and Cognitive Symptoms

Lion's Mane & Multiple Sclerosis

8 weeks

In the only human lion's mane cognitive trial, improved scores appeared at week 8 and held through week 16 — then fell significantly within 4 weeks of stopping. The trial enrolled people with mild cognitive impairment, not MS.

Mori et al., Phytotherapy Research, 2009

n=30

Participants in the only human lion's mane cognitive RCT

3 g/day

Dose used in that trial — twelve 250 mg tablets daily, not the 1 g often quoted

0

Human clinical trials testing lion's mane in MS patients

Mori et al., Phytotherapy Research, 2009

View as image ↗

MS fatigue is not ordinary tiredness. It can arrive before any physical exertion, it doesn't reliably respond to rest, and it appears to be driven by nervous system damage rather than by sleep or activity levels. Multiple sclerosis is a central nervous system disease whose neurological symptoms accumulate into disability over time and erode physical, medical and socioeconomic well-being — and fatigue is among the symptoms people report as most limiting.^[6]

The direct answer to whether lion's mane helps with MS fatigue and cognitive symptoms: the mechanisms are plausible, but the compound has never been tested in a person with MS. The research that does exist — one human cognitive trial from 2009, a 2023 discovery of a second memory-enhancing pathway, rodent demyelination models, and two 2025 reviews — is a foundation. It is not clinical proof for MS.

This article covers that research: what the mechanisms actually are, what the human data shows, what it doesn't show, and where the claims commonly circulated online part ways with the papers they cite. For a foundational overview of lion's mane biology, see our science-based lion's mane overview.

Why MS Fatigue Is Different — and Why That Changes What the Research Means

Ordinary fatigue has a relatively simple biology: energy demand exceeds energy supply, metabolic byproducts accumulate in muscle, the brain signals the body to rest. Sleep or rest resolves it.

MS fatigue works differently. Damaged myelin — the insulation that coats nerve fibres — forces the nervous system to work harder to transmit the same signals. Impulses that should travel quickly and efficiently instead require more metabolic effort per signal. Layered on top is chronic neuroinflammation: immune cells repeatedly infiltrate the brain and spinal cord, releasing inflammatory proteins that damage both myelin and the oligodendrocytes that produce it. A third strand is oxidative stress, which the 2025 review of medicinal mushrooms in MS identifies as one of the main targets mushroom compounds might plausibly address.^[6]

Mechanism mismatch · antifatigue evidence vs MS fatigue

The antifatigue research measures a different kind of tired

MS fatigue drivers from Pourmohammadi et al., Fitoterapia (2025). Antifatigue markers from Geng et al., International Journal of Medicinal Mushrooms (2017) and Friedman, J. Agric. Food Chem. (2015) — reviewed largely from rodent exertion models across edible and medicinal mushrooms, not from people with MS.

This is the single most important thing to understand before reading any "lion's mane for fatigue" claim: the overlap between what the antifatigue literature measures and what makes people with MS tired is narrow. Antioxidant capacity is the one place the two genuinely meet.

Three Mechanisms — and What Each One Was Actually Measured In

Lion's mane is proposed to affect cognitive symptoms through three biological routes. Each has been demonstrated at a different, and generally quite early, level of evidence.

1. NGF induction — and the hericenone caveat

Nerve growth factor (NGF) supports neuron survival and the connections between neurons. Mori and colleagues (2008) tested ethanol extracts of four edible mushrooms on NGF gene expression in 1321N1 human astrocytoma cells. Only the H. erinaceus extract raised NGF mRNA, and it did so in a concentration-dependent way; NGF protein secretion rose too, and the conditioned medium from those cells promoted neurite outgrowth in PC12 cells.^[7]

The detail almost universally dropped from popular summaries: in that same experiment, hericenones C, D and E failed to promote NGF gene expression. The activity belonged to the whole extract, not to the isolated hericenones. The authors traced the effect to JNK signalling — a JNK inhibitor abolished it.^[7]

Common claim

"Hericenones stimulate NGF"

The claim

“Hericenones in lion's mane fruiting bodies stimulate the brain to produce nerve growth factor.”

A compressed retelling of Mori et al. (2008), which is genuinely an NGF-induction paper — but not an NGF-induction-by-hericenones paper.

What research shows

Overstated

In Mori 2008, the crude H. erinaceus extract raised NGF mRNA and protein in astrocytoma cells, while hericenones C, D and E tested individually did not promote NGF gene expression at all.

Something in the extract induces NGF via JNK signalling. Which constituent is responsible was not resolved by that study, and attributing it specifically to hericenones goes beyond the data. Erinacines — found in mycelium rather than fruiting body — are a separate and better-supported candidate for direct neurotrophic activity.

Ref [7] Mori et al., 2008 (PMID 18758067)

2. ERK1/2 neurotrophic signalling

The 2023 paper by Martínez-Mármol and colleagues is the most mechanistically interesting entry in this literature. Working from hippocampal neurons, they isolated N-de phenylethyl isohericerin (NDPIH), an isoindoline compound, and its hydrophobic derivative hericene A. Both drove extensive axon outgrowth and neurite branching — even in serum-free conditions.^[2]

The key finding is about the route. Blocking the TrkB receptor with ANA-12 only partly prevented NDPIH's neurotrophic activity, and NDPIH went on to activate ERK1/2 signalling in HEK-293T cells that lack TrkB entirely. That makes it a pathway which converges on ERK1/2 without requiring TrkB — complementary to, rather than dependent on, conventional neurotrophin signalling. Mice fed either crude H. erinaceus extract or hericene A showed increased neurotrophin expression and significantly enhanced hippocampal memory.^[2]

Why TrkB-independence is worth noting for MS: TrkB responsiveness declines in aging and inflammatory brain conditions. A route that does not depend on it could remain available where TrkB signalling is compromised. That is a reasonable inference — it has not been tested in a demyelinating model.

3. Neuroinflammation suppression — measured in fat tissue

The cytokine result that circulates most widely comes from Mori et al. (2015). An ethyl acetate fraction of H. erinaceus suppressed TNF-α and IL-6 production in LPS-stimulated RAW264 macrophages, inhibited JNK activation, and blunted the inflammatory cross-talk between those macrophages and 3T3-L1 adipocytes. The authors attributed the effect to suppression of TLR4 signalling.^[8]

Key Study

Mori, Ouchi & Hirasawa (2015) · International Journal of Medicinal Mushrooms

Population

3T3-L1 adipocytes co-cultured with RAW264 macrophages (cell culture)

Intervention

Ethyl acetate soluble fraction of Hericium erinaceus (EAHE), with LPS stimulation

Finding

EAHE suppressed LPS-induced TNF-alpha and IL-6 production in macrophages, inhibited JNK activation, and prevented the LPS-induced fall in adiponectin mRNA. The authors attributed the effect to suppression of TLR4 signaling.

narrow-scope Well-conducted, but the system models obesity-related adipose inflammation. Macrophages and microglia are both myeloid cells sharing much of the TLR4-JNK machinery, so extending the reasoning to the MS brain is plausible — but it is reasoning, not a finding from this study.

Ref [8] Mori et al., 2015 (PMID 26559695)

Note also the apparent tension between mechanisms 1 and 3: in astrocytoma cells, JNK activation is what drives the NGF response; in macrophages, JNK inhibition is what reduces inflammatory cytokines. These are different cell types under different stimuli, so both can be true — but it is a reminder that "lion's mane modulates JNK" is not a single, directional effect that can be assumed to point the right way in the MS brain.

The Only Human Cognitive Trial: What Mori 2009 Found

For anyone researching lion's mane for cognitive symptoms, Mori 2009 is the piece of evidence to understand — including its limits.

The only human cognitive RCT

Mori, Inatomi, Ouchi, Azumi & Tuchida (2009) · Phytotherapy Research

Population

30 Japanese men and women aged 50–80 with mild cognitive impairment, randomised 15 vs 15

Intervention

Four 250 mg tablets of 96% H. erinaceus dry powder, three times daily (3 g/day), for 16 weeks, then 4 weeks off

Comparator

Matched placebo

Finding

The lion's mane group scored significantly higher on the Revised Hasegawa Dementia Scale than placebo at weeks 8, 12 and 16, with scores rising over the intake period. Four weeks after stopping, scores fell significantly. Laboratory tests showed no adverse effect.

preliminary A genuine, objectively-measured positive result — but a single small trial in a different population (MCI, not MS) with a benefit that disappeared once supplementation stopped.

Ref [1] Mori et al., 2009 (PMID 18844328)

Two details deserve emphasis because they are frequently reported incorrectly.

The dose was 3 g/day, not 1 g/day. Participants took four 250 mg tablets three times a day — twelve tablets, 3 grams of tablet material at 96% dry powder, so roughly 2.9 g of lion's mane dry matter daily.^[1] A great deal of supplement writing compresses this to "1 g/day" by counting a single dosing occasion instead of the daily total. It is a threefold error, and it matters: most consumer capsules deliver well under 1 g per serving, so matching the trial protocol would require substantially more product than a typical label suggests.

The benefit did not outlast the supplement. Four weeks after the 16-week intake ended, scores had fallen significantly.^[1] That points to an effect requiring continued intake rather than a lasting structural change — at least across a 16-week window.

What it does and doesn't tell people with MS. Mori 2009 is not an MS study. Mild cognitive impairment primarily involves memory formation and retrieval in older adults in the context of aging. MS cognitive impairment — often called "cog fog" — tends to involve processing speed, attention and working memory, occurs in younger adults, and arises against a background of active demyelination and inflammation. The result is the clearest human signal that lion's mane can move an objectively measured cognitive score. It is also the only such signal, and neither its size nor its mechanism can be assumed to carry across.

What the Rodent Demyelination Studies Actually Show

The MS-relevant evidence that goes beyond mechanism sits in animal models of demyelination — and it is more mixed than the summaries suggest.

Huang and colleagues (2021) found that H. erinaceus mycelium extract pushed oligodendrocyte precursor cells (OPCs) to mature into oligodendrocytes in culture and in cerebellar slices, raised myelin basic protein on neuronal fibres, and increased myelin markers in the corpus callosum of neonatal rat pups given the extract orally for 7 days.^[10] That is developmental myelination in healthy young animals, which is a different problem from repairing myelin in an inflamed adult brain.

Fu and colleagues (2024) came closer to the disease. Feeding rats a cuprizone diet to induce demyelination, they found that mycelium extract and erinacine S preserved myelin and oligodendrocytes in the corpus callosum, reduced microglial and astrocyte activation, and downregulated IL-1β. Erinacine S also worked as a post-treatment, given during the final 4 weeks of acute and chronic demyelination protocols.^[12] This is the strongest MS-adjacent result in the literature, and notably it is an erinacine — a mycelium compound — doing the work.

Yamashina and colleagues (2022) tested four mushrooms in cuprizone-demyelinated mice and produced the most useful negative detail. H. erinaceus did effectively suppress demyelination. But when it came to motor function, it was Pleurotus eryngii, Ganoderma lucidum and Flammulina velutipes — not H. erinaceus — that significantly improved cuprizone-induced motor dysfunction.^[11] Protecting myelin on a stain did not translate into the functional outcome in that experiment, which is precisely the gap that matters clinically.

For the deeper treatment of this evidence, see lion's mane and multiple sclerosis: remyelination research and Hericium erinaceus and oligodendrocyte differentiation.

Antifatigue Properties: What the Compound Research Actually Documents

Friedman's 2015 review in the Journal of Agricultural and Food Chemistry consolidated the chemistry of H. erinaceus and catalogued roughly 70 characterised actual and potential bioactive secondary metabolites. Antifatigue appears in its list of reported health-promoting properties, alongside anti-inflammatory, antioxidative and immunostimulating activities described across cells, animals and humans.^[5]

The mechanistic detail behind "antifatigue" comes from the broader mushroom literature rather than from lion's mane specifically. Geng and colleagues (2017) reviewed antifatigue effects across edible and medicinal mushrooms and concluded that they act through the muscular, cardiovascular, hormonal and immune systems, with polysaccharides, peptides, nucleosides, phenolic compounds and triterpenoids as the likely active constituents. Their closing caveat is the operative one: most of this work was done in animal models, and human trials are needed to confirm any antifatigue function.^[9]

The standard readouts in those rodent studies — blood lactate and urea nitrogen after forced exertion, liver and muscle glycogen, antioxidant enzyme activity — describe exertional fatigue. As the mismatch chart above makes explicit, only the antioxidant strand plausibly touches MS fatigue biology, because oxidative stress is one driver of myelin damage and is named as a mushroom-relevant target in the 2025 MS review.^[6] Reducing post-exercise lactate accumulation addresses a different process entirely.

Safety, Immune Activity, and the DMT Question

Safety

Moderate

Immune stimulation is not obviously desirable in an autoimmune disease

Concern

The 2025 review of medicinal mushrooms in MS lists increased immune system performance and increased B and T cells among the mechanisms proposed to explain benefit. In multiple sclerosis — a disease in which lymphocytes attack myelin — a compound that increases B- and T-cell activity is not self-evidently helpful, and most disease-modifying therapies work by doing the opposite.

What the research says

No study has measured lion's mane alongside interferon-beta, glatiramer acetate, natalizumab, or any other MS disease-modifying therapy. Whether the interaction would be neutral, additive, or counterproductive is unknown in both directions.

Particularly relevant for: People with MS, particularly those on immunosuppressant or immunomodulatory DMTs

What to do

Discuss any mushroom supplement with your treating neurologist before starting it, and treat the absence of interaction data as an open question rather than a clean bill of health.

Ref [6] Pourmohammadi et al., 2025 (PMID 40527388)

The 2025 systematic review by Menon and colleagues assessed the clinical literature on H. erinaceus against PRISMA methodology, screening PubMed for the period January 2000 to June 2024 and using the ROBIS tool for bias assessment. It drew on five randomised controlled trials, three pilot clinical trials, fifteen laboratory studies, a cohort study, a case report and a computational analysis.^[4]

On safety, its conclusion is more carefully worded than the "no side effects" framing common online: potential side effects include stomach discomfort, headache and allergic reactions, and the review explicitly notes these are commonly unreported in the underlying studies.^[4] Under-reporting means the absence of documented harm is weaker evidence of safety than it appears. Mori 2009's own laboratory testing did find no adverse effect over 16 weeks at 3 g/day, which is reassuring as far as it goes — one 15-person exposure arm.^[1]

Brandalise and colleagues' 2023 survey of H. erinaceus in neurodegenerative disease reaches the structural conclusion that governs this whole topic: preclinical work on the central nervous system is extensive and consistently ties erinacines to increased neurotrophic factor production, but only a limited number of clinical trials have been carried out, and wider trials are needed before safety and efficacy can be claimed.^[3] That review covers Alzheimer's disease, depression, Parkinson's disease and spinal cord injury — MS is not among the conditions it assesses.

This article is research summary, not medical advice. Nothing here is a recommendation to start, stop or change any supplement or MS treatment. Decisions about managing MS belong with your neurologist.

The Dosing Context: What the Human Protocol Looked Like

The Mori 2009 protocol is the only human clinical dosing data point for a cognitive outcome:

• Preparation: tablets of 96% H. erinaceus dry powder, fruiting body material
• Amount: four 250 mg tablets, three times daily — 3 g/day total
• Duration: 16 weeks, with benefit first significant at week 8
• Durability: scores fell significantly 4 weeks after intake stopped

Two caveats sit on top of applying this. The first is preparation. Mori 2009 used fruiting body dry powder; many consumer products use mycelium grown on grain, which carries a different compound profile — and, as Fu 2024 shows, the strongest demyelination result in the literature came from an erinacine, which is a mycelium compound rather than a fruiting-body one.^[12] The two preparation types are not interchangeable, and which is preferable depends on which mechanism you are hoping to engage.

The second is that none of this was measured in people with MS, at any dose.

For more on how preparation type changes the evidence, see can lion's mane repair myelin? evidence from preclinical studies and erinacines: the compounds that cross the blood-brain barrier. For the NGF pathway in detail, see hericenones and NGF synthesis.

Where the Research Gap Leaves People With MS

Laid out by how far each line of evidence has actually been carried, the picture is consistent — and the last column is empty.

Evidence reach · lion's mane and MS

Every mechanism stops short of an MS patient

Reach is the highest evidence tier reported for each mechanism in the studies cited in this article. “Human, not MS” is reached only by the Mori 2009 cognitive trial, whose participants had mild cognitive impairment. No cited study enrolled people with multiple sclerosis for any outcome.

The direction of travel is coherent: neurotrophic signalling that survives TrkB blockade, oligodendrocyte protection in a demyelinating rodent brain, an antioxidant strand that touches a real MS mechanism, and one human trial showing a measurable cognitive gain in a different population. The destination — benefit in a person with MS — has not been reached, and the honest reading of Yamashina 2022 is that even in rodents, protecting myelin did not automatically produce a functional improvement.

Related articles in this cluster go deeper: lion's mane and neuroinflammation: targeting the root of MS progression covers the inflammatory pathway evidence, and lion's mane and mild cognitive impairment covers the human cognitive trial data in full.

The Bottom Line

Lion's mane research relevant to MS fatigue and cognitive symptoms rests on three mechanisms — NGF induction in astrocytoma cells, TrkB-independent ERK1/2 neurotrophic signalling, and TLR4–JNK cytokine suppression demonstrated in adipose cell culture — plus rodent demyelination models in which H. erinaceus and erinacine S preserved myelin. The single human cognitive RCT (Mori 2009, n=30, 3 g/day for 16 weeks, MCI patients) found significant score gains at weeks 8, 12 and 16 that fell significantly within 4 weeks of stopping. Two frequently repeated claims do not survive contact with the sources: the trial dose was 3 g/day rather than 1 g/day, and the isolated hericenones did not induce NGF in the study usually cited for that claim. No trial has tested lion's mane in MS patients for any outcome.

Frequently Asked Questions

Does lion's mane help with MS fatigue?

No human trial has tested lion's mane for MS fatigue. The antifatigue evidence for mushrooms is largely from rodent exertion models measuring things like blood lactate, glycogen and antioxidant enzyme activity — exertional fatigue, which is a different biological process from the central fatigue that MS causes. The one place the two overlap is oxidative stress. The 2025 review of medicinal mushrooms in MS treats mushrooms as a candidate worth researching, not as an established option.

Can lion's mane help with MS brain fog?

The only human evidence for lion's mane improving cognition is Mori et al. (2009), a 30-person RCT in adults with mild cognitive impairment — not MS. Participants taking 3 g/day scored significantly better than placebo at weeks 8, 12 and 16. MS-related brain fog involves different mechanisms than MCI, primarily processing speed and attention affected by demyelination rather than memory affected by aging, and whether those results transfer is unknown.

What dose of lion's mane was used in the cognitive trial?

3 grams per day. Mori 2009 participants took four 250 mg tablets of 96% dry fruiting body powder three times daily — twelve tablets a day. This is frequently misreported as 1 g/day, which is one dosing occasion rather than the daily total. Most consumer capsules deliver well under a gram per serving, so the trial protocol is higher than many labels imply.

How long does lion's mane take to work for cognitive symptoms?

In Mori 2009 — the only controlled human cognitive trial — significant improvement first appeared at week 8 and continued through week 16. Within 4 weeks of stopping, scores fell significantly, which suggests the benefit depends on continued intake. That timeline was observed in older adults with MCI using a fruiting body powder at 3 g/day, and may not apply to other populations, preparations or doses.

Is lion's mane safe for people with MS?

Unknown, specifically. The 2025 systematic review lists stomach discomfort, headache and allergic reactions as potential side effects and notes they are commonly unreported in the underlying studies, which weakens any conclusion drawn from an apparent absence of harm. More relevant for MS: no study has examined lion's mane alongside disease-modifying therapies, and the 2025 MS mushroom review lists increased B- and T-cell activity among the proposed mechanisms — worth caution in an autoimmune disease. Discuss it with your neurologist before starting.

Sources & References

1. 1RTHM-00165·Mori, Koichiro et al. (2009). “Improving effects of the mushroom Yamabushitake (Hericium erinaceus) on mild cognitive impairment: a double-blind placebo-controlled clinical trial..” Phytotherapy research : PTR.Study breakdown →PubMed →↩
2. 2RTHM-01746·Martínez-Mármol, Ramón et al. (2023). “Hericerin derivatives activates a pan-neurotrophic pathway in central hippocampal neurons converging to ERK1/2 signaling enhancing spatial memory..” Journal of neurochemistry.Study breakdown →PubMed →↩
3. 3RTHM-01662·Brandalise, Federico et al. (2023). “Hericium erinaceus in Neurodegenerative Diseases: From Bench to Bedside and Beyond, How Far from the Shoreline?.” Journal of fungi (Basel.Study breakdown →PubMed →↩
4. 4RTHM-00943·Menon, Arya et al. (2025). “Benefits, side effects, and uses of Hericium erinaceus as a supplement: a systematic review..” Frontiers in nutrition.Study breakdown →PubMed →↩
5. 5RTHM-00371·Friedman, Mendel (2015). “Chemistry, Nutrition, and Health-Promoting Properties of Hericium erinaceus (Lion's Mane) Mushroom Fruiting Bodies and Mycelia and Their Bioactive Compounds..” Journal of agricultural and food chemistry.Study breakdown →PubMed →↩
6. 6RTHM-02163·Pourmohammadi, Golchehr et al. (2025). “New approach of using medicinal mushrooms for managing and curing multiple sclerosis..” Fitoterapia.Study breakdown →PubMed →↩
7. 7RTHM-00268·Mori, Koichiro et al. (2008). “Nerve growth factor-inducing activity of Hericium erinaceus in 1321N1 human astrocytoma cells..” Biological & pharmaceutical bulletin.Study breakdown →PubMed →↩
8. 8RTHM-00726·Mori, Koichiro et al. (2015). “The Anti-Inflammatory Effects of Lion's Mane Culinary-Medicinal Mushroom, Hericium erinaceus (Higher Basidiomycetes) in a Coculture System of 3T3-L1 Adipocytes and RAW264 Macrophages..” International journal of medicinal mushrooms.Study breakdown →PubMed →↩
9. 9RTHM-00871·Geng, Ping et al. (2017). “Antifatigue Functions and Mechanisms of Edible and Medicinal Mushrooms..” BioMed research international.Study breakdown →PubMed →↩
10. 10RTHM-00692·Huang, Hui-Ting et al. (2021). “Hericium erinaceus mycelium and its small bioactive compounds promote oligodendrocyte maturation with an increase in myelin basic protein..” Scientific reports.Study breakdown →PubMed →↩
11. 11RTHM-01637·Yamashina, Kota et al. (2022). “Suppressive Effect of Fruiting Bodies of Medicinal Mushrooms on Demyelination and Motor Dysfunction in a Cuprizone-Induced Multiple Sclerosis Mouse Model..” International journal of medicinal mushrooms.Study breakdown →PubMed →↩
12. 12RTHM-00878·Fu, Jing-Ting et al. (2024). “Erinacine S, a small active component derived from Hericium erinaceus, protects oligodendrocytes and alleviates mood abnormalities in cuprizone-exposed rodents..” Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.Study breakdown →PubMed →↩